Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and zd 6126

quinazolines has been researched along with zd 6126 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G1
Chambers, AF; Ellis, CG; Groom, AC; MacDonald, IC; Mackenzie, LT; Ryan, A; Varghese, HJ1
Shi, W; Siemann, DW1
Bozec, A; Fischel, JL; Formento, P; Gugenheim, J; Hofman, P; Lassalle, S; Milano, G1
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM1

Other Studies

5 other study(ies) available for quinazolines and zd 6126

ArticleYear
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors

2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.
    Angiogenesis, 2004, Volume: 7, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Line, Transformed; Disease Models, Animal; Female; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines

2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
    International journal of radiation oncology, biology, physics, 2004, Nov-15, Volume: 60, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines; Sarcoma, Kaposi

2004
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
    British journal of cancer, 2006, Sep-18, Volume: 95, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Organophosphorus Compounds; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays

2006
Cardiovascular toxicity profiles of vascular-disrupting agents.
    The oncologist, 2011, Volume: 16, Issue:8

    Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones

2011